DeflazacortThird Party Manufacturing in India

Deflazacort is a corticosteroid prodrug that is rapidly converted in the body to its active metabolite, 21-desDFZ. This active metabolite binds to the glucocorticoid receptor, a nuclear receptor that regulates gene transcription across multiple inflammatory pathways. Upon activation, the glucocorticoid receptor complex translocates to the cell nucleus where it modulates the expression of anti-inflammatory proteins while simultaneously suppressing pro-inflammatory mediators. The result is a broad suppression of the inflammatory cascade, including reduced production of cytokines, prostaglandins, and leukotrienes. Unlike some other glucocorticoids, deflazacort demonstrates a more favorable metabolic profile with significantly less impact on bone mineral density and weight gain, making it particularly suitable for pediatric patients who require long-term therapy. The drug exerts its therapeutic effects through both genomic pathways, which involve changes in gene expression over hours to days, and non-genomic pathways that produce more rapid cellular responses. By reducing tissue inflammation, suppressing immune cell activation, and stabilizing cellular membranes, deflazacort helps preserve muscle function and delay disease progression in chronic inflammatory conditions.

Therapeutic Uses

Deflazacort is primarily prescribed for the treatment of:

• Duchenne Muscular Dystrophy (DMD): Deflazacort is FDA-approved to manage DMD in patients aged 5 years and older. It helps preserve muscle strength and function, prolongs ambulation, and delays the onset of respiratory and cardiac complications associated with this progressive genetic disorder.
• Inflammatory and Autoimmune Conditions: As a glucocorticoid, it is used off-label for various inflammatory conditions including rheumatoid arthritis, asthma, allergic disorders, and inflammatory bowel disease where corticosteroid therapy is indicated.
• Immunosuppressive Therapy: The drug is sometimes employed as part of immunosuppressive regimens in transplant medicine and severe autoimmune disorders where modulation of the immune response is required.

Why Manufacturers Choose Deflazacort

The Indian pharmaceutical manufacturing market has shown growing interest in deflazacort due to its established position as a first-line therapy for Duchenne Muscular Dystrophy and its favorable side effect profile compared to prednisolone and other corticosteroids. The increasing diagnosis rates of DMD and expanding awareness of treatment options in India and emerging markets have created consistent demand for quality-assured deflazacort tablets. Multiple PCD pharma companies seek deflazacort manufacturing partners who can deliver WHO-GMP compliant products at competitive prices, making it a valued molecule for third party manufacturing operations in India.